Trials / Terminated
TerminatedNCT02608528
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer. Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response. PET/CT tumor metabolic response will also be correlated will to progression-free survival and overall survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | [18F]fluoroglucose(FDG) |
Timeline
- Start date
- 2015-10-22
- Primary completion
- 2019-07-18
- Completion
- 2019-07-18
- First posted
- 2015-11-18
- Last updated
- 2021-03-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02608528. Inclusion in this directory is not an endorsement.